FDA pilot opens provisional path for generative AI medical devices
STAT reports that the FDA has accepted four devices into its TEMPO pilot, allowing some digital health companies to release generative AI medical products without marketing authorization. The pilot is linked to a Medicare experiment and gives regulators practical experience with these systems.